CJC-1295 Peptide 2mg

CJC-1295 Peptide 2mg: Product Overview

CJC-1295 Peptide 2mg (No DAC), commonly identified as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). This research peptide contains a modified 29-amino-acid sequence investigated for its interaction with GHRH receptors and pathways involved in endogenous growth hormone secretion.

Unlike CJC-1295 DAC, the non-DAC peptide does not contain the albumin-binding Drug Affinity Complex modification. This structural difference is important when comparing molecular characteristics, pharmacokinetic behavior, and scientific research.

The 2mg designation identifies the stated quantity of peptide material in this product listing.

CJC-1295 2mg Product Specifications

• Product Name: CJC-1295 Peptide 2mg
• Common Alternative Names: CJC-1295 No DAC, Modified GRF (1-29), Mod GRF 1-29
• Peptide Type: Synthetic modified GHRH analog
• Classification: GHRH receptor agonist
• Peptide Length: 29 amino acid residues
• Molecular Formula: C152H252N44O42 (specified free-peptide structure)
• Molecular Weight: Approximately 3367.9 g/mol (specified free-peptide structure)
• DAC Modification: Not present
• Listed Quantity: 2mg
• Research Category: Growth Hormone Signaling
• Product Category: Research Peptides

These specifications describe the commonly referenced Modified GRF (1-29) structure. Because CJC-1295 naming conventions vary among suppliers, the actual peptide sequence and chemical form should be confirmed through batch-specific analytical documentation.

What Is CJC-1295 Without DAC?

CJC-1295 without DAC is a commercial designation commonly used for a modified growth hormone-releasing factor peptide. Its structure is derived from the biologically active N-terminal region of human GHRH.

The peptide contains selected amino acid substitutions designed to improve molecular stability compared with native GRF (1-29).

Unlike recombinant human growth hormone, this peptide acts through signaling pathways associated with the body's own hormone secretion system rather than providing the growth hormone protein directly.

Key Characteristics of CJC-1295 No DAC

• Modified GHRH Structure: A synthetic 29-amino-acid analog derived from growth hormone-releasing factor.
• GHRH Receptor Activity: Investigated for its interaction with receptors involved in pituitary growth hormone secretion.
• Structural Stability: Contains amino acid modifications intended to improve resistance to selected degradation pathways.
• Non-DAC Formulation: Does not contain the albumin-binding Drug Affinity Complex modification.
• Endocrine Research: Relevant to experimental investigations of growth hormone-related signaling.
• 2mg Presentation: Clearly identified peptide quantity for research documentation.

CJC-1295 No DAC Mechanism of Action

Modified GRF (1-29) is designed to interact with the growth hormone-releasing hormone receptor (GHRH-R), a receptor involved in regulating growth hormone secretion from the anterior pituitary gland.

Activation of this receptor can influence intracellular signaling associated with endogenous growth hormone release.

The modified peptide structure is intended to improve resistance to enzymatic degradation relative to native GRF (1-29). However, the pharmacokinetic properties of the non-DAC peptide should not be assumed to match those reported for CJC-1295 DAC.

CJC-1295 Peptide Research Background

Research involving modified GHRH analogs has focused on receptor interactions, pituitary signaling, peptide stability, and growth hormone secretion.

Modified GRF (1-29) belongs to this broader field of endocrine research. Its molecular modifications have attracted scientific interest in studies examining the relationship between peptide structure and biological activity.

Published human research frequently cited under the CJC-1295 name primarily concerns the DAC-containing compound. Those findings should not automatically be applied to CJC-1295 without DAC.

Clinical evidence specifically establishing the safety and effectiveness of commercially supplied non-DAC preparations remains limited.

CJC-1295 No DAC vs CJC-1295 DAC

CJC-1295 without DAC and CJC-1295 DAC are related GHRH analogs but differ in molecular structure and pharmacokinetic design.

• CJC-1295 No DAC: Commonly refers to a modified 29-amino-acid GRF analog without an albumin-binding modification.
• CJC-1295 DAC: Contains an additional chemical modification designed to bind serum albumin and extend peptide exposure.
• Molecular Difference: The DAC-containing compound includes an albumin-reactive linker absent from the non-DAC structure.
• Research Evidence: Published human pharmacokinetic results for CJC-1295 DAC do not establish equivalent values for the non-DAC analog.

These differences make exact peptide identification especially important when evaluating scientific information and product documentation.

CJC-1295 vs Ipamorelin

CJC-1295 without DAC and Ipamorelin are studied in growth hormone-related research, but they act through different receptor systems.

• CJC-1295 No DAC: A modified GHRH analog associated with GHRH receptor signaling.
• Ipamorelin: A synthetic pentapeptide that interacts with the growth hormone secretagogue receptor GHS-R1a.
• Primary Difference: The compounds have different amino acid structures and receptor targets.

Research findings involving these compounds should be evaluated separately.

CJC-1295 vs Human Growth Hormone (HGH)

CJC-1295 without DAC and recombinant human growth hormone are structurally and functionally different compounds.

CJC-1295 is a modified peptide intended to act through GHRH receptor signaling. Recombinant HGH is a complete 191-amino-acid protein hormone.

Their molecular identities, mechanisms, and experimental applications are distinct. CJC-1295 should not be considered equivalent to HGH.

CJC-1295 Peptide 2mg Product Documentation

The CJC-1295 Peptide 2mg product listing identifies a stated quantity of peptide material.

Product evaluation should include verification of the amino acid sequence, declared chemical form, absence of the DAC modification, peptide quantity, and available batch-specific analytical documentation.

Additional details may include identity testing, analytical purity information, and formulation-specific storage requirements.

CJC-1295 without DAC remains an investigational peptide. Its safety and effectiveness for therapeutic or performance-related applications have not been established.